Surrozen (SRZN) Stock Price, News & Analysis

Company Overview

Surrozen, Inc. is a clinical-stage biotechnology company developing regenerative medicines designed to activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen’s approach is intended to stimulate the pathway selectively in specific tissues while limiting unwanted effects elsewhere in the body.

The company’s product candidates are based on engineered antibody therapeutics and its proprietary SWEETS platform. Surrozen has focused its research on potential treatments for diseases affecting the liver, gastrointestinal system and eyes, where impaired tissue repair or abnormal signaling may contribute to disease progression. Its pipeline has included candidates such as SZN-043, SZN-1326 and SZN-413, which have been studied or developed for selected inflammatory, fibrotic and regenerative indications.

Surrozen was founded to translate advances in Wnt biology into medicines and became a publicly traded company on the Nasdaq under the symbol SRZN. As a development-stage biotechnology company, it has concentrated primarily on research, clinical development and partnerships rather than commercial product sales. The company’s programs remain subject to clinical, regulatory and funding risks typical of the biotechnology industry.

Key Stats

• Today's Range: $16.43 to $17.68
• 50-Day Range: $16.55 to $25.62
• 52-Week Range: $11.39 to $35.00
• Volume: 190,169 shs
• Average Volume: 183,416 shs
• Market Capitalization: $192.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Moderate Buy

Surrozen Stock Analysis - MarketRank™

Surrozen scored higher than 51% of companies evaluated by MarketBeat, and ranked 542nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Surrozen has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Surrozen has a consensus price target of $45.00, representing about 171.9% upside from its current price of $16.55.

Amount of Analyst Coverage

Surrozen has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Surrozen is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Surrozen is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.24% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 7.73.

Change versus previous month

Short interest in Surrozen has recently increased by 15.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surrozen does not currently pay a dividend.

Dividend Growth

Surrozen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.67

News Sentiment

Surrozen has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Surrozen this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Surrozen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,906,250.00 in company stock.

Percentage Held by Insiders

31.74% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SRZN
• CIK: 1824893
• Web: www.surrozen.com
• Phone: 650-489-9000
• Fax: N/A
• Employees: 44
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Surrozen: $45.00
• High Price Target: $51.00
• Low Price Target: $40.00
• Potential Upside/Downside: +171.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($40.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$242.03 million
• Net Margins: -2,885.33%
• Pretax Margin: -2,885.33%
• Return on Equity: N/A
• Return on Assets: -93.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.14
• Quick Ratio: 12.14

Sales & Book Value

• Annual Sales: $3.48 million
• Price / Sales: 55.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($19.21) per share
• Price / Book: -0.86

Miscellaneous

• Outstanding Shares: 11,610,000
• Free Float: 7,925,000
• Market Cap: $192.15 million
• Optionable: Not Optionable
• Beta: 0.56